4D Molecular Therapeutics, Inc.
FDMT
$6.54
$0.396.34%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -54.66M | -47.97M | -49.67M | -43.84M | -34.95M |
Total Depreciation and Amortization | 1.89M | 1.75M | 1.78M | 1.70M | 1.62M |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 3.80M | 5.63M | 5.74M | 4.29M | 3.77M |
Change in Net Operating Assets | 5.59M | -7.17M | -3.72M | 8.46M | -688.00K |
Cash from Operations | -43.38M | -47.76M | -45.86M | -29.39M | -30.24M |
Capital Expenditure | -66.00K | -631.00K | -949.00K | -1.78M | -349.00K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -13.79M | 32.58M | 8.01M | 29.08M | -73.19M |
Cash from Investing | -13.85M | 31.95M | 7.06M | 27.30M | -73.54M |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 862.00K | -- | 601.00K | 568.00K | 17.25M |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 862.00K | -- | 601.00K | 568.00K | 17.25M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -56.37M | -15.81M | -38.20M | -1.52M | -86.53M |